Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
1(33.3%)
Phase 2
1(33.3%)
N/A
1(33.3%)
3Total
Phase 4(1)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06809166Phase 4Recruiting

Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity

Role: collaborator

NCT06997107Not ApplicableActive Not Recruiting

AI to Create Accessible & Reliable Patient Education Materials

Role: collaborator

NCT03147859Phase 2Unknown

Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection

Role: collaborator

NCT04369690Unknown

The Psychological, Social, and Economic Impacts of COVID-19

Role: collaborator

All 4 trials loaded